Search results
Results from the WOW.Com Content Network
Amgen Inc. v. Sanofi, 598 U.S. 594 (2023), is a United States Supreme Court case in which the Court held that Amgen's two patent applications on cholesterol-lowering drugs failed to satisfy the enablement clause of §112 of the Patent Act, 35 U.S.C. § 112(a).
The following are settlements reached with US authorities against pharmaceutical companies to resolve allegations of "off-label" promotion of drugs. Under the Federal Food, Drug, and Cosmetic Act, it is illegal for pharmaceutical companies to promote their products for uses not approved by the Food and Drug Administration (FDA), and corporations that market drugs for off-label indications may ...
Amgen's acquisition of Horizon was the first biotech deal challenged since the FTC's 2021 launch of a pharmaceutical merger task force, which has been followed by workshops designed to explore ...
AMGen corporate logo, 1983 Argentine president Mauricio Macri meets with heads of Amgen, in 2018. Amgen was established in Thousand Oaks in 1980, as Applied Molecular Genetics. [6] [7] Amgen was backed by a small group of venture capitalists, and its early focus was on recombinant DNA technology and recombinant human insulin. [8]
Amgen announced Wednesday that it has finalized an agreement with the U.S. government, 49 states, and the District of Columbia resolving investigations into promotional practices for six drugs ...
But with the pharma industry in the crosshairs for pricing, Amgen is keeping a focus on increased volumes of its products. "In 2018, this industry turned from price increases for 35 years or so to ...
The settlement involved requirements that Amgen refrain from bundling any of its products with two Horizon medicines: Tepezza, which treats thyroid eye disease, or a medicine for chronic gout ...
Founded in 1958, PhRMA lobbies on behalf of pharmaceutical companies. [ 2 ] [ 3 ] PhRMA is headquartered in Washington, D.C. [ 1 ] The organization has lobbied fiercely against allowing Medicare to negotiate drug prices for Medicare recipients, [ 4 ] and filed lawsuits against the drug price provisions in the Inflation Reduction Act . [ 5 ]